文献速递前列腺癌

孤立性寡复发前列腺癌中不联合雄激素剥夺治疗的转移灶导向治疗

Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer.
PubMed 文献 · J Urol · 2022-11-09

研究纳入2008至2018年Mayo Clinic C-11胆碱PET登记中124例原发灶已治疗、PET显示孤立性寡复发转移灶且接受不联合雄激素剥夺治疗的转移灶导向治疗的前列腺癌患者。手术组3年影像学无进展生存率为29%,立体定向体部放疗组为17%。作者认为该治疗可延迟全身治疗启动,并需进一步前瞻性研究。

要点

  • 124例孤立性寡复发前列腺癌患者接受不联合雄激素剥夺治疗的转移灶导向治疗。
  • 手术组首次随访PSA下降>50%者占80.5%,3年影像学无进展生存率为29%。
  • 立体定向体部放疗组首次随访PSA下降>50%者占40.3%,3年影像学无进展生存率为17%。

核心结论

  • 本研究是首报的不联合雄激素剥夺治疗用于孤立性寡复发转移性前列腺癌患者的转移灶导向治疗系列,结果提示该治疗可延迟全身治疗启动,并需对特定孤立性转移复发患者进一步前瞻性研究。

研究设计与样本

  • 从Mayo Clinic C-11胆碱登记中识别2008至2018年124例原发灶已治疗、PET显示孤立性寡复发转移灶且接受不联合雄激素剥夺治疗的转移灶导向治疗的前列腺癌患者。
  • 转移灶导向治疗为立体定向体部放疗或手术切除。
  • 手术组67例,中位随访54个月;立体定向体部放疗组57例,中位随访53个月。

主要发现

  • 手术组首次随访PSA下降>50%者占80.5%,3年影像学无进展生存率为29%,启动全身治疗的中位时间为18.5个月(四分位距8.4-44.7个月)。
  • 立体定向体部放疗组首次随访PSA下降>50%者占40.3%,3年影像学无进展生存率为17%,启动全身治疗的中位时间为17.8个月(四分位距7.1-42.3个月)。

关键数值与推荐

  • 手术组3年影像学无进展生存率为29%,立体定向体部放疗组为17%。
  • 手术组启动全身治疗的中位时间为18.5个月(四分位距8.4-44.7个月),立体定向体部放疗组为17.8个月(四分位距7.1-42.3个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需对特定孤立性转移复发前列腺癌患者进一步前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As controversy remains regarding the role of metastasis-directed therapy in patients with oligometastatic prostate cancer, we sought to characterize outcomes of metastasis-directed therapy without concomitant androgen deprivation therapy in the specific subset of patients with a solitary metastatic lesion on C-11 choline positron emission tomography imaging whose primary tumor has already been treated. MATERIALS AND METHODS: We identified 124 consecutive prostate cancer patients from 2008 to 2018 with a solitary oligorecurrent metastatic lesion on positron emission tomography imaging who were treated with metastasis-directed therapy without androgen deprivation therapy from the Mayo Clinic C-11 choline registry. Metastasis-directed therapy consisted of either stereotactic body radiation therapy or surgical excision. RESULTS: Of these 124 patients, 67 were treated with surgery (median follow-up 54 months) and 57 patients were treated with stereotactic body radiation therapy (median follow-up 53 months). Of patients treated with surgery, 80.5% had >50% decline in prostate specific antigen at first follow-up, and the 3-year radiographic progression-free survival was 29%. Median time to initiation of systemic therapy in this cohort was 18.5 months (interquartile range 8.4-44.7 months). Meanwhile, for patients treated with stereotactic body radiation therapy, 40.3% had >50% decline in prostate specific antigen at first follow-up, and the 3-year radiographic progression-free survival was 17%. Similarly, median time to initiation of systemic therapy was 17.8 months (interquartile range 7.1-42.3 months). CONCLUSIONS: This study represents the first reported series of metastasis-directed therapy without androgen deprivation therapy in patients with solitary oligorecurrent metastatic prostate cancer. These results suggest that metastasis-directed therapy without androgen deprivation therapy can delay initiation of systemic therapy and highlight the need for further prospective study for select patients with solitary metastatic recurrences of prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Andrews JR, Ahmed ME, Sharma V, et al. Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer. J Urol. 2022. PMID: 36349914. doi:10.1097/JU.0000000000002898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。